Matinas BioPharma Holdings Inc (MTNB) - Total Liabilities
Based on the latest financial reports, Matinas BioPharma Holdings Inc (MTNB) has total liabilities worth $2.85 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Matinas BioPharma Holdings Inc cash flow conversion to assess how effectively this company generates cash.
Matinas BioPharma Holdings Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Matinas BioPharma Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Check Matinas BioPharma Holdings Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Matinas BioPharma Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Matinas BioPharma Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
Indonesia | Rp797.31 Billion |
|
Caledonia Mining Corporation Plc
LSE:CMCL
|
UK | GBX116.79 Million |
|
Marshalls PLC
LSE:MSLH
|
UK | GBX430.70 Million |
|
Reliance Global Group Inc
NASDAQ:RELI
|
USA | $6.37 Million |
|
Nordic Asia Investment Group 1987 AB Series B
ST:NAIG-B
|
Sweden | Skr15.54 Million |
|
Henderson High Income Trust
LSE:HHI
|
UK | GBX67.03 Million |
|
Great Atlantic Resources Corp
V:GR
|
Canada | CA$6.14 Million |
|
Aquaporin AS
CO:AQP
|
Denmark | Dkr101.12 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Matinas BioPharma Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Matinas BioPharma Holdings Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Matinas BioPharma Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Matinas BioPharma Holdings Inc (2012–2025)
The table below shows the annual total liabilities of Matinas BioPharma Holdings Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.38 Million | -52.92% |
| 2024-12-31 | $5.05 Million | -13.78% |
| 2023-12-31 | $5.86 Million | -86.13% |
| 2022-12-31 | $42.23 Million | +378.14% |
| 2021-12-31 | $8.83 Million | +22.05% |
| 2020-12-31 | $7.24 Million | +0.66% |
| 2019-12-31 | $7.19 Million | +89.11% |
| 2018-12-31 | $3.80 Million | +1.60% |
| 2017-12-31 | $3.74 Million | +40.33% |
| 2016-12-31 | $2.67 Million | +14.26% |
| 2015-12-31 | $2.33 Million | +105.87% |
| 2014-12-31 | $1.13 Million | +31.97% |
| 2013-12-31 | $858.97K | +917.41% |
| 2012-12-31 | $84.43K | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more